Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 10, 2010 - Issue 5
Submit an article Journal homepage
143
Views
17
CrossRef citations to date
0
Altmetric
Drug Profile

Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder

Roger S McIntyre Associate Professor, Department of Psychiatry, University of Toronto, Toronto, ON, Canada and Associate Professor, Department of Pharmacology, University of Toronto, Toronto, ON, Canada and Institute of Medical Science, University of Toronto, Toronto, ON, Canada and Head, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada. [email protected]
Pages 645-649 | Published online: 09 Jan 2014

References

  • McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry66(Suppl. 3), 28–36 (2005).
  • Ng F, Mammen OK, Wilting I et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord.11(6), 559–595 (2009).
  • Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry67(4), 509–516 (2006).
  • Tohen M, Bowden CL, Calabrese JR et al. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br. J. Psychiatry189, 515–519 (2006).
  • Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am. J. Psychiatry163(2), 217–224 (2006).
  • Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J. Clin. Psychopharmacol.24(5 Suppl. 1), S1–S6 (2004).
  • McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord.11(7), 673–686 (2009).
  • McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord.11(8), 815–826 (2009).
  • McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J. Affect. Disord.122(1–2), 27–38 (2010).
  • Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr. Dis. Treat.5, 483–490 (2009).
  • Tarazi FI, Choi YK, Gardner M, Wong EH, Henry B, Shahid M. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse63(5), 413–420 (2009).
  • Marston HM, Young JW, Martin FD et al. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl.)206(4), 699–714 (2009).
  • Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl.)198(1), 103–111 (2008).
  • Franberg O, Marcus MM, Ivanov V, Schilstrom B, Shahid M, Svensson TH. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl.)204(2), 251–264 (2009).
  • Ghanbari R, El Mansari M, Shahid M, Blier P. Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, α2-adrenergic and D2 receptors in the rat brain. Eur. Neuropsychopharmacol.19(3), 177–187 (2009).
  • Choi YK, Wong EH, Henry B, Shahid M, Tarazi FI. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int. J. Neuropsychopharmacol.19, 1–6 (2009).
  • Belmaker RH. Patient history must be incorporated into any guidelines. Bipolar Disord.11(7), 772 (2009).
  • Frye MA, Ketter TA, Leverich GS et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J. Clin. Psychiatry61(1), 9–15 (2000).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.